U.S. POINTER study leadership has been closely monitoring the novel coronavirus (COVID-19) situation. Based on guidance from the Centers for Disease Control and local authorities, we have determined that it is safe to restart in-person research activities.
Please know that we will continue to monitor the situation and will take recommended precautions to protect the health and safety of U.S. POINTER participants and staff.
The Alzheimer's Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is a two-year clinical trial to evaluate whether lifestyle interventions that simultaneously target many risk factors protect cognitive function in older adults who are at increased risk for cognitive decline. U.S. POINTER is the first such study to be conducted in a large group of Americans across the United States.
Read about U.S. POINTER study leadership and our principal investigators.
Find out more about the eligibility requirements and locations of the study.
Browse helpful Alzheimer's disease information on alz.org.
In 2014, a large-scale two-year study in Finland in healthy older adults at increased risk of cognitive decline and dementia (the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability, or FINGER Study) reported that a two-year combination therapy simultaneously targeting physical exercise, a healthy diet, cognitive stimulation, and self-monitoring of heart health risk factors had a protective effect on cognitive function. FINGER and U.S. POINTER join other similar efforts around the globe in a worldwide consortium, World Wide FINGERS (WW-FINGERS). WW-FINGERS will align these research efforts focused on the prevention of Alzheimer's disease and other dementias across the globe.
Whether you are a researcher or potential participant, use this contact information to receive answers to your questions regarding U.S. POINTER.